<inglise> REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products </inglise>
<eesti> EUROOPA PARLAMENDI JA N&Otilde;UKOGU M&Auml;&Auml;RUS (E&Uuml;) nr 141/2000 harva kasutatavate ravimite kohta 16. detsember 1999 </eesti>
<inglise> THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, </inglise>
<eesti> EUROOPA PARLAMENT JA EUROOPA LIIDU N&Otilde;UKOGU, </eesti>
<inglise> Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa &Uuml;henduse asutamislepingut, eriti selle artiklit 95, </eesti>
<inglise> Having regard to the proposal from the Commission(1), </inglise>
<eesti> v&otilde;ttes arvesse komisjoni ettepanekut, (1) </eesti>
<inglise> Having regard to the opinion of the Economic and Social Committee(2), </inglise>
<eesti> v&otilde;ttes arvesse majandus- ja sotsiaalkomitee arvamust, (2) </eesti>
<inglise> Acting in accordance with the procedure laid down in Article 251 of the Treaty(3), </inglise>
<eesti> tegutsedes asutamislepingu artiklis 251 etten&auml;htud korras (3) </eesti>
<inglise> Whereas: </inglise>
<eesti> ning arvestades, et: </eesti>
<inglise> (1) some conditions occur so infrequently that the cost of developing and bringing to the market a medicinal product to diagnose, prevent or treat the condition would not be recovered by the expected sales of the medicinal product; the pharmaceutical industry would be unwilling to develop the medicinal product under normal market conditions; these medicinal products are called "orphan"; </inglise>
<eesti> 1) m&otilde;nda haigusseisundit tuleb ette nii harva, et selle diagnoosimiseks, v&auml;ltimiseks v&otilde;i ravimiseks vajaliku ravimi eeldatav m&uuml;&uuml;k ei korvaks ravimi arendamise ja turuletoomise kulusid; farmaatsiat&ouml;&ouml;stus ei sooviks seda ravimit tavalistes turutingimustes arendada; neid ravimeid nimetatakse "harva kasutatavateks"; </eesti>
<inglise> (2) patients suffering from rare conditions should be entitled to the same quality of treatment as other patients; it is therefore necessary to stimulate the research, development and bringing to the market of appropriate medications by the pharmaceutical industry; incentives for the development of orphan medicinal products have been available in the United States of America since 1983 and in Japan since 1993; </inglise>
<eesti> 2) haruldaste haigusseisundite all kannatavatel patsientidel peaks olema &otilde;igus samav&auml;&auml;rsele ravile kui teistel patsientidel; seet&otilde;ttu on vaja ergutada farmaatsiat&ouml;&ouml;stuses sobivate ravimite uuringuid, arendamist ja turuletoomist; soodustused harva kasutatavate ravimite arendamiseks on Ameerika &Uuml;hendriikides k&auml;ttesaadavad alates aastast 1983 ja Jaapanis aastast 1993; </eesti>
<inglise> (3) in the European Union, only limited action has been taken so far, whether at national or at Community level, to stimulate the development of orphan medicinal products; such action is best taken at Community level in order to take advantage of the widest possible market and to avoid the dispersion of limited resources; action at Community level is preferable to uncoordinated measures by the Member States which may result in distortions of competition and barriers to intra-Community trade; </inglise>
<eesti> 3) seni on Euroopa Liidus nii siseriiklikul kui &uuml;henduse tasandil v&otilde;etud ainult piiratud meetmeid, et ergutada harva kasutatavate ravimite arendamist; selliseid meetmeid on k&otilde;ige parem v&otilde;tta &uuml;henduse tasandil, et kasutada &auml;ra v&otilde;imalikult avarat turgu ja v&auml;ltida piiratud varude hajutamist; meetmed &uuml;henduse tasandil on eelistatavamad kui liikmesriikide koosk&otilde;lastamata meetmed, mis v&otilde;ivad p&otilde;hjustada konkurentsikahjustusi ja &uuml;hendusesisese kaubanduse t&otilde;kkeid; </eesti>
<inglise> (4) orphan medicinal products eligible for incentives should be easily and unequivocally identified; it seems most appropriate to achieve this result through the establishment of an open and transparent Community procedure for the designation of potential medicinal products as orphan medicinal products; </inglise>
<eesti> 4) soodustuste tingimustele vastavad harva kasutatavad ravimid peaksid olema lihtsalt ja selges&otilde;naliselt eristatavad; selle saavutamiseks tundub sobivaim avatud ja l&auml;bipaistva &uuml;henduse menetluse kehtestamine teatavate ravimite nimetamiseks harva kasutatavateks ravimiteks; </eesti>
<inglise> (5) objective criteria for designation should be established; those criteria should be based on the prevalence of the condition for which diagnosis, prevention or treatment is sought; a prevalence of not more than five affected persons per 10 thousand is generally regarded as the appropriate threshold; medicinal products intended for a life-threatening, seriously debilitating or serious and chronic condition should be eligible even when the prevalence is higher than five per 10 thousand; </inglise>
<eesti> 5) tuleks kehtestada nimetamise objektiivsed kriteeriumid; need kriteeriumid peaksid p&otilde;hinema diagnoosimist, v&auml;ltimist v&otilde;i ravi n&otilde;udvate haigusseisundite esinemissagedusel; sobivaks l&auml;veks peetakse &uuml;ldiselt esinemissagedust mitte rohkem kui viis haigusjuhtu k&uuml;mne tuhande inimese kohta; ravimid, mis on m&otilde;eldud eluohtliku, t&otilde;siselt invaliidistava v&otilde;i t&otilde;sise ja kroonilise haigusseisundi ravimiseks, peaksid tingimustele vastama isegi juhul, kui esinemissagedus on suurem kui viis k&uuml;mnest tuhandest; </eesti>
<inglise> (6) a Committee composed of experts appointed by the Member States should be established to examine applications for designation; this Committee should also include three representatives of patients' associations, designated by the Commission, and three other persons, also designated by the Commission, on a recommendation from the European Agency for the Evaluation of Medicinal Products (hereinafter referred to as "the Agency"); the Agency should be responsible for the adequate coordination between the Committee on orphan medicinal products and the Committee on proprietary medicinal products; </inglise>
<eesti> 6) nimetamistaotluste l&auml;bivaatamiseks tuleks luua liikmesriikide m&auml;&auml;ratud ekspertidest komitee; samuti peaks sellesse komiteesse kuuluma kolm komisjoni m&auml;&auml;ratud esindajat patsientide &uuml;hingutest ja kolm samuti komisjoni m&auml;&auml;ratud muud isikut Euroopa Ravimihindamisameti (edaspidi "amet") soovituse p&otilde;hjal; amet peaks vastutama piisava koosk&otilde;lastuse eest harva kasutatavate ravimite komitee ja ravimpreparaatide komitee vahel; </eesti>
<inglise> (7) patients with such conditions deserve the same quality, safety and efficacy in medicinal products as other patients; orphan medicinal products should therefore be submitted to the normal evaluation process; sponsors of orphan medicinal products should have the possibility of obtaining a Community authorisation; in order to facilitate the granting or the maintenance of a Community authorisation, fees to be paid to the Agency should be waived at least in part; the Community budget should compensate the Agency for the loss in revenue thus occasioned; </inglise>
<eesti> 7) sellistes haigusseisundites patsiendid v&auml;&auml;rivad samasuguse kvaliteedi, turvalisuse ja t&otilde;hususega ravimeid kui muud patsiendid; harva kasutatavad ravimid tuleks seet&otilde;ttu allutada harilikule hindamismenetlusele; harva kasutatavate ravimite sponsoritel peaks olema v&otilde;imalus saada &uuml;henduse luba; et h&otilde;lbustada &uuml;henduse loa andmist v&otilde;i s&auml;ilitamist, tuleks ametile makstavatest l&otilde;ivudest v&auml;hemalt osaliselt loobuda; ametile sellest tekkinud tulude kaotus tuleks h&uuml;vitada &uuml;henduse eelarvest; </eesti>
<inglise> (8) experience in the United States of America and Japan shows that the strongest incentive for industry to invest in the development and marketing of orphan medicinal products is where there is a prospect of obtaining market exclusivity for a certain number of years during which part of the investment might be recovered; data protection under Article 4(8) (a) (iii) of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products(4) is not a sufficient incentive for that purpose; Member States acting independently cannot introduce such a measure without a Community dimension as such a provision would be contradictory to Directive 65/65/EEC; if such measures were adopted in an uncoordinated manner by the Member States, this would create obstacles to intra-Community trade, leading to distortions of competition and running counter to the single market; market exclusivity should however be limited to the therapeutic indication for which orphan medicinal product designation has been obtained, without prejudice to existing intellectual property rights; in the interest of patients, the market exclusivity granted to an orphan medicinal product should not prevent the marketing of a similar medicinal product which could be of significant benefit to those affected by the condition; </inglise>
<eesti> 8) Ameerika &Uuml;henduriikide ja Jaapani kogemus n&auml;itab, et k&otilde;ige paremini innustab t&ouml;&ouml;stust harva kasutatavate ravimite arendamisse ja turustamisse investeerima v&auml;ljavaade saada turul ainu&otilde;igus teatavateks aastateks, mille v&auml;ltel v&otilde;ib tagasi saada osa investeeringust; ravimeid k&auml;sitlevate &otilde;igusnormide &uuml;htlustamist k&auml;sitleva n&otilde;ukogu 26. jaanuari 1965. aasta direktiivi 65/65/EM&Uuml; (4) artikli 4 l&otilde;ike 8 punkti a alapunktile iii vastav andmekaitse ei ole soodustusena piisav; eraldi tegutsedes ei saaks liikmesriigid kehtestada niisugust meedet ilma &uuml;henduse tasandita, sest selline s&auml;te oleks vastuolus direktiiviga 65/65/EM&Uuml;; kui liikmesriigid v&otilde;taksid selliseid meetmeid koosk&otilde;lastamata viisil, tekitaks see &uuml;hendusesiseses kaubanduses t&otilde;kkeid, mis tooksid kaasa konkurentsikahjustusi ja t&ouml;&ouml;taksid vastu &uuml;histurule; ainu&otilde;igus turul peaks siiski olema piiratud selle n&auml;idustusega, mille jaoks ravim on saanud harva kasutatava ravimi nimetuse, piiramata olemasolevaid intellektuaalomandi &otilde;igusi; patsientide huvides ei tohiks harva esinevale ravimile antud ainu&otilde;igus turul takistada turustamast sarnast ravimit, millest v&otilde;ib olla m&auml;rkimisv&auml;&auml;rset kasu selle haigusseisundi all kannatajatele; </eesti>
<inglise> (9) sponsors of orphan medicinal products designated under this Regulation should be entitled to the full benefit of any incentives granted by the Community or by the Member States to support the research and development of medicinal products for the diagnosis, prevention or treatment of such conditions, including rare diseases; </inglise>
<eesti> 9) k&auml;esoleva m&auml;&auml;ruse kohaselt nimetatud harva kasutatavate ravimite sponsoritel peaks olema t&auml;ielik &otilde;igus kasutada k&otilde;iki &uuml;henduse v&otilde;i liikmesriikide antud soodustusi, et uurida ja arendada selliste haigusseisundite ja haruldaste haiguste diagnoosimiseks, v&auml;ltimiseks v&otilde;i raviks m&otilde;eldud ravimeid; </eesti>
<inglise> (10) the specific programme Biomed 2, of the fourth framework programme for research and technological development (1994 to 1998), supported research on the treatment of rare diseases, including methodologies for rapid schemes for the development of orphan medicinal products and inventories of available orphan medicinal products in Europe; those grants were intended to promote the establishment of cross national cooperation in order to implement basic and clinical research on rare diseases; research on rare diseases continues to be a priority for the Community, as it has been included in the fifth framework programme for research and technological development (1998 to 2002); this Regulation establishes a legal framework which will allow the swift and effective implementation of the outcome of this research; </inglise>
<eesti> 10) neljanda teadusuuringute ja tehnika arengu raamprogrammi (1994 - 1998) eriprogramm Biomed 2 toetas haruldaste haiguste ravi uurimist, sealhulgas meetodeid, kuidas kiiresti v&auml;lja arendada harva kasutatavaid ravimeid ja koostada Euroopas k&auml;ttesaadavate harva kasutatavate ravimite registrit; need toetused olid kavandatud riikidevahelisele koost&ouml;&ouml;le, et edendada haruldaste haiguste &uuml;ldist ja kliinilist uurimist; haruldaste haiguste uurimine on j&auml;tkuvalt &uuml;henduse prioriteet, see on l&uuml;litatud viiendasse teadusuuringute ja tehnoloogia arengu raamprogrammi (1998 - 2002); k&auml;esolev m&auml;&auml;rus kehtestab &otilde;igusraamistiku, mis v&otilde;imaldab nende uuringutulemusi kiiresti ja t&otilde;husalt rakendada; </eesti>
<inglise> (11) rare diseases have been identified as a priority area for Community action within the framework for action in the field of public health; the Commission, in its communication concerning a programme of Community action on rare diseases within the framework for action in the field of public health has decided to give rare diseases priority within the public health framework; the European Parliament and the Council have adopted Decision No 1295/1999/EC of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003) (5), including actions to provide information, to deal with clusters of rare diseases in a population and to support relevant patient organisations; this Regulation implements one of the priorities laid down in this programme of action, </inglise>
<eesti> 11) haruldased haigused on nimetatud &uuml;henduse meetmete eelistatud alaks rahvatervise valdkonnas; komisjon on oma teatises &uuml;henduse tegevuse kohta haruldaste haiguste alal rahvatervise valdkonnas otsustanud anda haruldastele haigustele eelistuse rahvatervise valdkonnas; Euroopa Parlament ja n&otilde;ukogu on vastu v&otilde;tnud 29. aprilli 1999. aasta otsuse nr 1295/1999/E&Uuml;, millega v&otilde;etakse vastu &uuml;henduse tegevuskava haruldaste haiguste osas rahvatervise valdkonnas (1999 - 2003), (5) kaasa arvatud meetmed teabe andmise, elanikkonnas haruldaste haiguspuhangutega tegelemise ja asjaomaste patsientide organisatsioonide toetamise kohta; k&auml;esoelva m&auml;&auml;rus rakendab &uuml;ht selles tegevuskavas etten&auml;htud prioriteetidest, </eesti>
<inglise> HAVE ADOPTED THIS REGULATION: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA M&Auml;&Auml;RUSE. </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> Purpose </inglise>
<eesti> Eesm&auml;rk </eesti>
<inglise> The purpose of this Regulation is to lay down a Community procedure for the designation of medicinal products as orphan medicinal products and to provide incentives for the research, development and placing on the market of designated orphan medicinal products. </inglise>
<eesti> K&auml;esoleva m&auml;&auml;ruse eesm&auml;rk on s&auml;testada &uuml;henduse menetlus ravimite nimetamiseks harva kasutatavateks ravimiteks ja n&auml;ha ette soodustused nimetatud harva kasutatavate ravimite uuringuteks, arendamiseks ja turuleviimiseks. </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> Definitions </inglise>
<eesti> M&otilde;isted </eesti>
<inglise> For the purposes of this Regulation: </inglise>
<eesti> K&auml;esolevas m&auml;&auml;ruses kasutatakse j&auml;rgmisi m&otilde;isteid: </eesti>
<inglise> (a) "medicinal product" means a medicinal product for human use, as defined in Article 2 of Directive 65/65/EEC; </inglise>
<eesti> a) ravim - direktiivi 65/65/EM&Uuml; artiklis 2 m&auml;&auml;ratletud inimtervishoius kasutatav ravim; </eesti>
<inglise> (b) "orphan medicinal product" means a medicinal product designated as such under the terms and conditions of this Regulation; </inglise>
<eesti> b) harva kasutatav ravim - ravim, mis on saanud sellise nimetuse vastavalt k&auml;esoleva m&auml;&auml;ruse tingimustele; </eesti>
<inglise> (c) "sponsor" means any legal or natural person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product; </inglise>
<eesti> c) sponsor - iga juriidiline v&otilde;i f&uuml;&uuml;siline isik &uuml;henduses, kes soovib saavutada v&otilde;i on saavutanud ravimi nimetamise harva kasutatavaks ravimiks; </eesti>
<inglise> (d) "Agency" means the European Agency for the Evaluation of Medicinal Products. </inglise>
<eesti> d) amet - Euroopa Ravimihindamisamet. </eesti>
<inglise> Article 3 </inglise>
<eesti> Artikkel 3 </eesti>
<inglise> Criteria for designation </inglise>
<eesti> Nimetamise kriteeriumid </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> A medicinal product shall be designated as an orphan medicinal product if its sponsor can establish: </inglise>
<eesti> Ravim nimetatakse harva kasutatavaks ravimiks, kui tema sponsor t&otilde;endab: </eesti>
<inglise> (a) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand persons in the Community when the application is made, or </inglise>
<eesti> a) et see on kavandatud taotluse esitamise ajal &uuml;henduses mitte rohkemat kui viit inimest k&uuml;mnest tuhandest m&otilde;jutava eluohtliku v&otilde;i j&auml;&auml;valt invaliidistava haigusseisundi diagnoosimiseks, v&auml;ltimiseks v&otilde;i raviks v&otilde;i </eesti>
<inglise> that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and that without incentives it is unlikely that the marketing of the medicinal product in the Community would generate sufficient return to justify the necessary investment; </inglise>
<eesti> et see on kavandatud eluohtliku, t&otilde;siselt invaliidistava v&otilde;i t&otilde;sise ja kroonilise haigusseisundi diagnoosimiseks, v&auml;ltimiseks v&otilde;i raviks &uuml;henduses ning et ilma soodustusteta ei ole t&otilde;en&auml;oline, et ravimi turustamine &uuml;henduses annaks piisavat tulu vajaliku investeeringu &otilde;igustamiseks; </eesti>
<inglise> and </inglise>
<eesti> ja </eesti>
<inglise> (b) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorised in the Community or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition. </inglise>
<eesti> b) et k&otilde;nealuse haigusseisundi diagnoosimiseks, v&auml;ltimiseks v&otilde;i ravimiseks ei ole &uuml;henduses heakskiidetud rahuldavat meetodit v&otilde;i et sellise meetodi olemasolu korral toob ravim selle haigusseisundi t&otilde;ttu kannatajatele m&auml;rkimisv&auml;&auml;rset kasu. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The Commission shall adopt the necessary provisions for implementing this Article in the form of an implementing Regulation in accordance with the procedure laid down in Article 72 of Council Regulation (EEC) No 2309/93(6). </inglise>
<eesti> Komisjon v&otilde;tab k&auml;soleva artikli rakendamiseks vajalikud s&auml;tted rakendusm&auml;&auml;ruse kujul n&otilde;ukogu m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 (6) artiklis 72 etten&auml;htud korras. </eesti>
<inglise> Article 4 </inglise>
<eesti> Artikkel 4 </eesti>
<inglise> Committee for Orphan Medicinal Products </inglise>
<eesti> Harva kasutatavate ravimite komitee </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> A Committee for Orphan Medicinal Products, hereinafter referred to as "the Committee", is hereby set up within the Agency. </inglise>
<eesti> K&auml;esolevaga luuakse ametis harva kasutatavate ravimite komitee, edaspidi "komitee". </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The task of the Committee shall be: </inglise>
<eesti> Komitee &uuml;lesanne on: </eesti>
<inglise> (a) to examine any application for the designation of a medicinal product as an orphan medicinal product which is submitted to it in accordance with this Regulation; </inglise>
<eesti> a) vaadata l&auml;bi iga talle vastavalt k&auml;esolevale m&auml;&auml;rusele esitatud taotlus ravimi nimetamiseks harva kasutatavaks ravimiks; </eesti>
<inglise> (b) to advise the Commission on the establishment and development of a policy on orphan medicinal products for the European Union; </inglise>
<eesti> b) n&otilde;ustada komisjoni harva kasutatavate ravimite poliitika kehtestamisel ja kujundamisel Euroopa Liidus; </eesti>
<inglise> (c) to assist the Commission in liaising internationally on matters relating to orphan medicinal products, and in liaising with patient support groups; </inglise>
<eesti> c) aidata komisjoni harva kasutatavate ravimitega seotud rahvusvahelises koost&ouml;&ouml;s ning sidemetes patsientide tugir&uuml;hmadega; </eesti>
<inglise> (d) to assist the Commission in drawing up detailed guidelines. </inglise>
<eesti> d) aidata komisjonil koostada &uuml;ksikasjalikud suunised. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The Committee shall consist of one member nominated by each Member State, three members nominated by the Commission to represent patients' organisations and three members nominated by the Commission on the basis of a recommendation from the Agency. </inglise>
<eesti> Komitee koosseis on j&auml;rgmine: iga liikmesriik nimetab &uuml;he liikme, komisjon nimetab kolm liiget, kes esindavad patsientide organisatsioone, ja kolm liiget, kelle komisjon nimetab ameti soovituse alusel. </eesti>
<inglise> The members of the Committee shall be appointed for a term of three years, which shall be renewable. </inglise>
<eesti> Komitee liikmete ametiaeg on kolm aastat ja neid v&otilde;ib uueks ametiajaks tagasi nimetada. </eesti>
<inglise> They may be accompanied by experts. </inglise>
<eesti> Neile v&otilde;ivad abiks olla eksperdid. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> The Committee shall elect its Chairman for a term of three years, renewable once. </inglise>
<eesti> Komitee valib oma eesistuja kolmeks aastaks, teda saab &uuml;ks kord tagasi valida. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> The representatives of the Commission and the Executive Director of the Agency or his representative may attend all meetings of the Committee. </inglise>
<eesti> Komisjoni esindajad ja ameti tegevdirektor v&otilde;i tema esindaja v&otilde;ivad osa v&otilde;tta k&otilde;igist komitee koosolekutest. </eesti>
<inglise> 6. </inglise>
<eesti> 6. </eesti>
<inglise> The Agency shall provide the secretariat of the Committee. </inglise>
<eesti> Amet tagab komiteele sekretariaaditeenused. </eesti>
<inglise> 7. </inglise>
<eesti> 7. </eesti>
<inglise> Members of the Committee shall be required, even after their duties have ceased, not to disclose any information of the kind covered by the obligation of professional secrecy. </inglise>
<eesti> Komitee liikmetelt n&otilde;utakse isegi p&auml;rast kohustuste l&otilde;ppemist, et nad ei avaldaks mingit ametisaladuse alla kuuluvat teavet. </eesti>
<inglise> Article 5 </inglise>
<eesti> Artikkel 5 </eesti>
<inglise> Procedure for designation and removal from the register </inglise>
<eesti> Nimetamise kord ja registrist kustutamine </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> In order to obtain the designation of a medicinal product as an orphan medicinal product, the sponsor shall submit an application to the Agency at any stage of the development of the medicinal product before the application for marketing authorisation is made. </inglise>
<eesti> Ravimile harva kasutatava ravimi nimetuse saamiseks esitab sponsor ametile taotluse &uuml;ksk&otilde;ik millisel ravimi arenduse etapil enne m&uuml;&uuml;giloa taotlemist. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The application shall be accompanied by the following particulars and documents: </inglise>
<eesti> Taotlust peavad olema lisatud j&auml;rgmised &uuml;ksikasjad ja dokumendid: </eesti>
<inglise> (a) name or corporate name and permanent address of the sponsor; </inglise>
<eesti> a) sponsori nimi v&otilde;i &auml;rinimi ja alaline elu- v&otilde;i asukoht; </eesti>
<inglise> (b) active ingredients of the medicinal product; </inglise>
<eesti> b) ravimi toimeained; </eesti>
<inglise> (c) proposed therapeutic indication; </inglise>
<eesti> c) kavandatav n&auml;idustus; </eesti>
<inglise> (d) justification that the criteria laid down in Article 3(1) are met and a description of the stage of development, including the indications expected. </inglise>
<eesti> d) artikli 3 l&otilde;ikes 1 s&auml;testatud kriteeriumidele vastavuse p&otilde;hjendus ja arendusetapi kirjeldus, kaasa arvatud eeldatavad n&auml;idustused. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The Commission shall, in consultation with the Member States, the Agency and interested parties, draw up detailed guidelines on the required format and content of applications for designation. </inglise>
<eesti> Komisjon koostab liikmesriikide, ameti ja huvitatud osapooltega konsulteerides &uuml;ksikasjalikud suunised nimetamistaotluste vormi ja sisu kohta. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> The Agency shall verify the validity of the application and prepare a summary report to the Committee. </inglise>
<eesti> Amet kontrollib taotluse kehtivust ja koostab komiteele kokkuv&otilde;tliku aruande. </eesti>
<inglise> Where appropriate, it may request the sponsor to supplement the particulars and documents accompanying the application. </inglise>
<eesti> Vajaduse korral v&otilde;ib ta n&otilde;uda sponsorilt taotlusele lisatud &uuml;ksikasjade ja dokumentide t&auml;iendamist. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> The Agency shall ensure that an opinion is given by the Committee within 90 days of the receipt of a valid application. </inglise>
<eesti> Amet tagab, et komitee esitab oma arvamuse 90 p&auml;eva jooksul p&auml;rast n&otilde;uetekohase taotluse saamist. </eesti>
<inglise> 6. </inglise>
<eesti> 6. </eesti>
<inglise> When preparing its opinion, the Committee shall use its best endeavours to reach a consensus. </inglise>
<eesti> Arvamust ette valmistades annab komitee endast parima, et j&otilde;uda &uuml;ksmeelele. </eesti>
<inglise> If such a consensus cannot be reached, the opinion shall be adopted by a majority of two-thirds of the members of the Committee. </inglise>
<eesti> Kui &uuml;ksmeelele ei j&otilde;uta, v&otilde;etakse arvamus vastu kahe kolmandiku komitee liikmete h&auml;&auml;lteenamusega. </eesti>
<inglise> The opinion may be obtained by written procedure. </inglise>
<eesti> Arvamuse v&otilde;ib vastu v&otilde;tta kirjalikus menetluses. </eesti>
<inglise> 7. </inglise>
<eesti> 7. </eesti>
<inglise> Where the opinion of the Committee is that the application does not satisfy the criteria set out in Article 3(1), the Agency shall forthwith inform the sponsor. </inglise>
<eesti> Kui komitee arvamus on, et taotlus ei vasta artikli 3 l&otilde;ikes 1 etten&auml;htud kriteeriumidele, teatab amet sellest viivitamatult sponsorile. </eesti>
<inglise> Within 90 days of receipt of the opinion, the sponsor may submit detailed grounds for appeal, which the Agency shall refer to the Committee. </inglise>
<eesti> 90 p&auml;eva jooksul p&auml;rast arvamuse k&auml;ttesaamist v&otilde;ib sponsor asja vaidlustamiseks esitada &uuml;ksikasjalikud p&otilde;hjused, mille amet edastab komiteele. </eesti>
<inglise> The Committee shall consider whether its opinion should be revised at the following meeting. </inglise>
<eesti> Komitee otsustab, kas arvamus tuleb uuesti l&auml;bi vaadata j&auml;rgmisel koosolekul. </eesti>
<inglise> 8. </inglise>
<eesti> 8. </eesti>
<inglise> The Agency shall forthwith forward the final opinion of the Committee to the Commission, which shall adopt a decision within 30 days of receipt of the opinion. </inglise>
<eesti> Amet edastab komitee l&otilde;pliku arvamuse viivitamatult komisjonile, kes teeb otsuse 30 p&auml;eva jooksul p&auml;rast arvamuse saamist. </eesti>
<inglise> Where, in exceptional circumstances, the draft decision is not in accordance with the opinion of the Committee, the decision shall be adopted in accordance with the procedure laid down in Article 73 of Regulation (EEC) No 2309/93. </inglise>
<eesti> Erandjuhtudel, kui otsuse eeln&otilde;u ei ole koosk&otilde;las komitee arvamusega, v&otilde;etakse otsus vastu m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 artiklis 73 etten&auml;htud korras. </eesti>
<inglise> The decision shall be notified to the sponsor and communicated to the Agency and to the competent authorities of the Member States. </inglise>
<eesti> Otsus teatatakse sponsorile ja edastatakse ametile ning liikmesriikide p&auml;devatele asutustele. </eesti>
<inglise> 9. </inglise>
<eesti> 9. </eesti>
<inglise> The designated medicinal product shall be entered in the Community Register of Orphan Medicinal Products. </inglise>
<eesti> Harva kasutatava ravimi nimetuse saanud ravim kantakse &uuml;henduse harva kasutatavate ravimite registrisse. </eesti>
<inglise> 10. </inglise>
<eesti> 10. </eesti>
<inglise> Each year the sponsor shall submit to the Agency a report on the state of development of the designated medicinal product. </inglise>
<eesti> Igal aastal esitab sponsor ametile aruande harva kasutatava ravimi nimetuse saanud ravimi arendamise olukorra kohta. </eesti>
<inglise> 11. </inglise>
<eesti> 11. </eesti>
<inglise> To have the designation of an orphan medicinal product transferred to another sponsor, the holder of the designation shall make specific application to the Agency. </inglise>
<eesti> Harva kasutatava ravimi nimetuse &uuml;leandmiseks teisele sponsorile esitab nimetuse valdaja ametile eritaotluse. </eesti>
<inglise> In consultation with the Member States, the Agency and interested parties, the Commission shall draw up detailed guidelines on the form in which applications for transfer shall be made and the content of such applications and all the particulars of the new sponsor. </inglise>
<eesti> Konsulteerides liikmesriikide, ameti ja huvitatud isikutega koostab komisjon &uuml;ksikasjalikud juhendid &uuml;leandmistaotluste konkreetse vormi ja sisu ning k&otilde;igi uue sponsori &uuml;ksikasjade kohta. </eesti>
<inglise> 12. </inglise>
<eesti> 12. </eesti>
<inglise> A designated orphan medicinal product shall be removed from the Community Register of Orphan Medicinal Products: </inglise>
<eesti> Harva kasutatava ravimi nimetuse saanud ravim tuleb &uuml;henduse harva kasutatavate ravimite registrist kustutada: </eesti>
<inglise> (a) at the request of the sponsor; </inglise>
<eesti> a) kui sponsor seda taotleb; </eesti>
<inglise> (b) if it is established before the market authorisation is granted that the criteria laid down in Article 3 are no longer met in respect of the medicinal product concerned; </inglise>
<eesti> b) juhul, kui enne m&uuml;&uuml;giloa andmist t&otilde;estatakse, et k&otilde;nealune ravim ei vasta enam artikli 3 kriteeriumidele; </eesti>
<inglise> (c) at the end of the period of market exclusivity as laid down in Article 8. </inglise>
<eesti> c) kui l&otilde;peb artiklis 8 s&auml;testatud ainu&otilde;igus turul. </eesti>
<inglise> Article 6 </inglise>
<eesti> Artikkel 6 </eesti>
<inglise> Protocol assistance </inglise>
<eesti> Abi ravimi v&auml;ljat&ouml;&ouml;tamiseks </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The sponsor of an orphan medicinal product may, prior to the submission of an application for marketing authorisation. request advice from the Agency on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product, in accordance with Article 51(j) of Regulation (EEC) No 2309/93. </inglise>
<eesti> Harva kasutatava ravimi sponsor v&otilde;ib enne m&uuml;&uuml;giloa taotluse esitamist vastavalt m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 artikli 51 punktile j taotleda ametilt n&otilde;uannet, et viia l&auml;bi mitmesugused ravimi kvaliteedi, turvalisuse ja t&otilde;hususe n&auml;itamiseks vajalikud katsed ja uuringud. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The Agency shall draw up a procedure on the development of orphan medicinal products, covering regulatory assistance for the definition of the content of the application for authorisation within the meaning of Article 6 of Regulation (EEC) No 2309/93. </inglise>
<eesti> Amet koostab harva kasutatavate ravimite arendamise korra, mis n&auml;eb ette &otilde;igusabi m&uuml;&uuml;giloa taotluse sisu m&auml;&auml;ratlemiseks m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 artikli 6 t&auml;henduses. </eesti>
<inglise> Article 7 </inglise>
<eesti> Artikkel 7 </eesti>
<inglise> Community marketing authorisation </inglise>
<eesti> &Uuml;henduse m&uuml;&uuml;giluba </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> The person responsible for placing on the market an orphan medicinal product may request that authorisation to place the medicinal product on the market be granted by the Community in accordance with the provisions of Regulation (EEC) No 2309/93 without having to justify that the medicinal product qualifies under Part B of the Annex to that Regulation. </inglise>
<eesti> Harva kasutatava ravimi turuleviimise eest vastutav isik v&otilde;ib &uuml;henduselt taotleda ravimi m&uuml;&uuml;giluba vastavalt m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 s&auml;tetele, ilma et ta peaks p&otilde;hjendama ravimi vastavust selle m&auml;&auml;ruse lisa B osale. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> A special contribution from the Community, distinct from that provided for in Article 57 of Regulation (EEC) No 2309/93, shall be allocated every year to the Agency. </inglise>
<eesti> Ametile m&auml;&auml;ratakse igal aastal &uuml;henduse poolt spetsiaalne summa, mis erineb m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 artiklis 57 s&auml;testatust. </eesti>
<inglise> The contribution shall be used exclusively by the Agency to waive, in part or in total, all the fees payable under Community rules adopted pursuant to Regulation (EEC) No 2309/93. </inglise>
<eesti> Amet peab seda summat kasutama ainult selleks, et osaliselt v&otilde;i t&auml;ielikult loobuda k&otilde;igist &uuml;henduse eeskirjadega etten&auml;htud l&otilde;ivudest, mis on vastu v&otilde;etud m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 kohaselt. </eesti>
<inglise> A detailed report of the use made of this special contribution shall be presented by the Executive Director of the Agency at the end of each year. </inglise>
<eesti> Ameti tegevdirektor esitab iga aasta l&otilde;pus selle summa kasutamise kohta &uuml;ksikasjaliku aruande. </eesti>
<inglise> Any surplus occurring in a given year shall be carried forward and deducted from the special contribution for the following year. </inglise>
<eesti> Iga konkreetsel aastal tekkiv &uuml;lej&auml;&auml;k kantakse &uuml;le ja lahutatakse j&auml;rgmise aasta selleks etten&auml;htud summast. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> The marketing authorisation granted for an orphan medicinal product shall cover only those therapeutic indications which fulfil the criteria set out in Article 3. </inglise>
<eesti> Harva kasutatavale ravimile antud m&uuml;&uuml;giluba h&otilde;lmab ainult artiklis 3 s&auml;testatud kriteeriumidele vastavaid n&auml;idustusi. </eesti>
<inglise> This is without prejudice to the possibility of applying for a separate marketing authorisation for other indications outside the scope of this Regulation. </inglise>
<eesti> See ei piira v&otilde;imalust taotleda eraldi m&uuml;&uuml;giluba muude, k&auml;esoleva m&auml;&auml;ruse reguleerimisalast v&auml;ljaj&auml;&auml;vate n&auml;idustuste kohta. </eesti>
<inglise> Article 8 </inglise>
<eesti> Artikkel 8 </eesti>
<inglise> Market exclusivity </inglise>
<eesti> Ainu&otilde;igus turul </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where a marketing authorisation in respect of an orphan medicinal product is granted pursuant to Regulation (EEC) No 2309/93 or where all the Member States have granted marketing authorisations in accordance with the procedures for mutual recognition laid down in Articles 7 and 7a of Directive 65/65/EEC or Article 9(4) of Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products(7), and without prejudice to intellectual property law or any other provision of Community law, the Community and the Member States shall not, for a period of 10 years, accept another application for a marketing authorisation, or grant a marketing authorisation or accept an application to extend an existing marketing authorisation, for the same therapeutic indication, in respect of a similar medicinal product. </inglise>
<eesti> Kui harva kasutatavale ravimile antakse m&uuml;&uuml;giluba vastavalt m&auml;&auml;rusele (EM&Uuml;) nr 2309/93 v&otilde;i kui k&otilde;ik liikmesriigid on andnud m&uuml;&uuml;giload vastavalt direktiivi 65/65/EM&Uuml; artiklites 7 ja 7a v&otilde;i ravimeid k&auml;sitlevate &otilde;igusnormide &uuml;htlustamise kohta vastuv&otilde;etud n&otilde;ukogu 20. mai 1975. aasta direktiivi 75/319/EM&Uuml; (7) artikli 9 l&otilde;ikes 4 s&auml;testatud vastastikuse tunnustamise korrale ning piiramata intellektuaalomandi&otilde;igust v&otilde;i &uuml;htki muud &uuml;henduse &otilde;iguse s&auml;tet, ei v&otilde;i &uuml;hendus ega liikmesriigid 10 aasta jooksul vastu v&otilde;tta uut sama n&auml;idustusega sarnase ravimi m&uuml;&uuml;giloa taotlust ega anda m&uuml;&uuml;giluba v&otilde;i vastu v&otilde;tta olemasoleva m&uuml;&uuml;giloa pikendamise taotlust. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> This period may however be reduced to six years if, at the end of the fifth year, it is established, in respect of the medicinal product concerned, that the criteria laid down in Article 3 are no longer met, inter alia, where it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. </inglise>
<eesti> Seda t&auml;htaega v&otilde;ib l&uuml;hendada kuue aastani juhul, kui viienda aasta l&otilde;pul t&otilde;estatakse, et asjaomase ravimi puhul ei t&auml;ideta enam artiki 3 kriteeriume, muu hulgas juhul, kui k&auml;ttesaadavate t&otilde;endite p&otilde;hjal n&auml;idatakse, et toode on piisavalt tulus ja ainu&otilde;iguse s&auml;ilitamine turul ei ole p&otilde;hjendatud. </eesti>
<inglise> To that end, a Member State shall inform the Agency that the criterion on the basis of which market exclusivity was granted may not be met and the Agency shall then initiate the procedure laid down in Article 5. </inglise>
<eesti> Sel eesm&auml;rgil teatab liikmesriik ametile, et turul ainu&otilde;igust andvat kriteeriumi v&otilde;idakse enam mitte t&auml;ita, ja amet algatab siis artiklis 5 s&auml;testatud menetluse. </eesti>
<inglise> The sponsor shall provide the Agency with the information necessary for that purpose. </inglise>
<eesti> Sponsor peab ametile andma vajaliku teabe. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> By way of derogation from paragraph 1, and without prejudice to intellectual property law or any other provision of Community law, a marketing authorisation may be granted, for the same therapeutic indication, to a similar medicinal product if: </inglise>
<eesti> Erandina l&otilde;ikest 1 ja piiramata intellektuaalomandi&otilde;igust v&otilde;i &uuml;htki teist &uuml;henduse &otilde;iguse s&auml;tet v&otilde;ib sama n&auml;idustusega sarnasele ravimile anda m&uuml;&uuml;giloa juhul, kui: </eesti>
<inglise> (a) the holder of the marketing authorisation for the original orphan medicinal product has given his consent to the second applicant, or </inglise>
<eesti> a) algse harva kasutatava ravimi m&uuml;&uuml;giloa valdaja on teisele taotlejale andnud oma n&otilde;usoleku v&otilde;i </eesti>
<inglise> (b) the holder of the marketing authorisation for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product, or </inglise>
<eesti> b) algse harva kasutatava ravimi m&uuml;&uuml;giloa valdaja ei suuda tarnida ravimit piisavas koguses v&otilde;i </eesti>
<inglise> (c) the second applicant can establish in the application that the second medicinal product, although similar to the orphan medicinal product already authorised, is safer, more effective or otherwise clinically superior. </inglise>
<eesti> c) teine taotleja suudab taotluses t&otilde;estada, et teine ravim, kuigi juba loa saanud harva kasutatava ravimiga sarnane, on ohutum, t&otilde;husam v&otilde;i muul viisil kliiniliselt parem. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> The Commission shall adopt definitions of "similar medicinal product" and "clinical superiority" in the form of an implementing Regulation in accordance with the procedure laid down in Article 72 of Regulation (EEC) No 2309/93. </inglise>
<eesti> Komisjon kehtestab rakendusm&auml;&auml;ruses "sarnase ravimi" ja "kliinilise paremuse" m&auml;&auml;ratlused m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 artiklis 72 etten&auml;htud korras. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> The Commission shall draw up detailed guidelines for the application of this Article in consultation with the Member States, the Agency and interested parties. </inglise>
<eesti> Komisjon koostab k&auml;esoleva artikli rakendamise &uuml;ksikasjalikud suunised, konsulteerides liikmesriikide, ameti ja huvitatud isikutega. </eesti>
<inglise> Article 9 </inglise>
<eesti> Artikkel 9 </eesti>
<inglise> Other incentives </inglise>
<eesti> Muud soodustused </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Community and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. </inglise>
<eesti> Vastavalt k&auml;esoleva m&auml;&auml;ruse s&auml;tetele harva kasutatavateks ravimiteks nimetatud ravimid vastavad soodustuste saamise tingimustele, mida &uuml;hendus ja liikmesriigid pakuvad, et toetada harva kasutatavate ravimite uurimist, arendamist ning k&auml;ttesaadavust, eelk&otilde;ige teadusuuringute ja tehnoloogia arengu raamprogrammides v&auml;ikestele ja keskmise suurusega ettev&otilde;tetele uuringuteks etten&auml;htud abi saamise tingimustele. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> Before 22 July 2000, the Member States shall communicate to the Commission detailed information concerning any measure they have enacted to support research into, and the development and availability of, orphan medicinal products or medicinal products that may be designated as such. </inglise>
<eesti> Enne 22. juulit 2000 edastavad liikmesriigid komisjonile &uuml;ksikasjaliku teabe k&otilde;igi meetmete kohta, mis nad on v&otilde;tnud harva kasutatavate ravimite v&otilde;i seda nimetust saada v&otilde;ivate ravimite uurimise, arendamise ja k&auml;ttesaadavuse toetamiseks. </eesti>
<inglise> That information shall be updated regularly. </inglise>
<eesti> Seda teavet ajakohastatakse korrap&auml;raselt. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> Before 22 January 2001, the Commission shall publish a detailed inventory of all incentives made available by the Community and the Member States to support research into, and the development and availability of, orphan medicinal products. </inglise>
<eesti> Enne 22. jaanuari 2001 avaldab komisjon &uuml;ksikasjaliku nimistu k&otilde;igist harva kasutatavate ravimite uurimise, arendamise ja k&auml;ttesaadavuse toetamiseks &uuml;henduses ja liikmesriikides pakutavate soodustuste kohta. </eesti>
<inglise> That inventory shall be updated regularly. </inglise>
<eesti> Seda nimistut ajakohastatakse korrap&auml;raselt. </eesti>
<inglise> Article 10 </inglise>
<eesti> Artikkel 10 </eesti>
<inglise> General report </inglise>
<eesti> &Uuml;ldaruanne </eesti>
<inglise> Before 22 January 2006, the Commission shall publish a general report on the experience acquired as a result of the application of this Regulation, together with an account of the public health benefits which have been obtained. </inglise>
<eesti> Enne 22. jaanuari 2006 avaldab komisjon k&auml;esoleva m&auml;&auml;ruse kohaldamisest saadud kogemuste &uuml;ldaruande koos rahvatervisele toodud kasu aruandega. </eesti>
<inglise> Article 11 </inglise>
<eesti> Artikkel 11 </eesti>
<inglise> Entry into force </inglise>
<eesti> J&otilde;ustumine </eesti>
<inglise> This Regulation shall enter into force on the day of its publication in the Official Journal of the European Communities. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus j&otilde;ustub Euroopa &Uuml;henduste Teatajas avaldamise p&auml;eval. </eesti>
<inglise> It shall apply as from the date of adoption of the implementing Regulations provided for in Article 3(2) and Article 8(4). </inglise>
<eesti> Seda kohaldatakse alates artikli 3 l&otilde;ikes 2 ja artikli 8 l&otilde;ikes 4 etten&auml;htud rakendusm&auml;&auml;ruste vastuv&otilde;tmise kuup&auml;evast. </eesti>
<inglise> This Regulation shall be binding in its entirety and directly applicable in all Member States. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus on tervikuna siduv ja vahetult kohaldatav k&otilde;ikides liikmesriikides. </eesti>
<inglise> Done at Brussels, 16 December 1999. </inglise>
<eesti> Br&uuml;ssel, 16. detsember 1999 </eesti>
<inglise> For the European Parliament </inglise>
<eesti> Euroopa Parlamendi nimel </eesti>
<inglise> The President </inglise>
<eesti> president </eesti>
<inglise> N. FONTAINE </inglise>
<eesti> N. FONTAINE </eesti>
<inglise> For the Council </inglise>
<eesti> N&otilde;ukogu nimel </eesti>
<inglise> The President </inglise>
<eesti> eesistuja </eesti>
<inglise> K. HEMIL&Auml; </inglise>
<eesti> K. HEMIL&Auml; </eesti>
<inglise> (1) OJ C 276, 4.9.1998, p. 7. </inglise>
<eesti> (1) E&Uuml;T C 276, 4.09.1998, lk 7. </eesti>
<inglise> (2) OJ C 101, 12.4.1999, p. 37. </inglise>
<eesti> (2) E&Uuml;T C 101, 12.04.1999, lk 37. </eesti>
<inglise> (3) Opinion of the European Parliament of 9 March 1999 (OJ C 175, 21.6.1999, p. 61), Council Common Position of 27 September 1999 (OJ C 317, 4.11.1999, p. 34) and Decision of the European Parliament of 15 December 1999 (not yet published in the Official Journal). </inglise>
<eesti> (3) Euroopa Parlamendi 9. m&auml;rtsi 1999. aasta arvamus (E&Uuml;T C 175, 21.06.1999, lk 61), n&otilde;ukogu 27. septembri 1999. aasta &uuml;hisseisukoht (E&Uuml;T C 317, 4.11.1999, lk 34) ja Euroopa Parlamendi 15. detsembri 1999. aasta otsus (E&Uuml;Ts veel avaldamata). </eesti>
<inglise> (4) OJ 22, 9.2.1965, p. 369. Directive as last amended by Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22). </inglise>
<eesti> (4) E&Uuml;T 22, 9.02.1965, lk 369. Direktiivi on viimati muudetud direktiiviga 93/39/EM&Uuml; (E&Uuml;T L 214, 24.08.1993, lk 22). </eesti>
<inglise> (5) OJ L 155, 22.6.1999, p. 1. </inglise>
<eesti> (5) E&Uuml;T L 155, 22.06.1999, lk 1. </eesti>
<inglise> (6) OJ L 214, 24.8.1993, p. 1. Regulation as amended by Commission Regulation (EC) No 649/98 (OJ L 88, 24.3.1998, p. 7). </inglise>
<eesti> (6) E&Uuml;T L 214, 24.08.1993, lk 1. M&auml;&auml;rust on muudetud komisjoni m&auml;&auml;rusega (E&Uuml;) nr 649/98 (E&Uuml;T L 88, 24.03.1998, lk 7). </eesti>
<inglise> (7) OJ L 147, 9.6.1975, p. 13. Directive as last amended by Council Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22). </inglise>
<eesti> (7) E&Uuml;T L 147, 9.06.1975, lk 13. Direktiivi on viimati muudetud n&otilde;ukogu direktiiviga 93/39/EM&Uuml; (E&Uuml;T L 214, 24.08.1993, lk 22). </eesti>
 